Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Starting soon Not applicable

Effectiveness of Digital Health Management on Patients With Head and Neck Vascular Stenosis

NCT05798013 · tracked via the Priya Life Science China tracker
Sponsor
Phase
Not applicable
Started
2025-10
Last updated
2024-10-02

Condition(s) studied

Head and Neck Vascular Stenosis

Investigational drug(s) / intervention(s)

Digital health management

Digital health management: The digital health management platform mainly includes reminding patients to take medication on time, monitoring and managing risk factors, reminding patients of regular review and regular follow-up, pushing personalized science according to patients' risk factors, etc., as well as following up and supervising patients' health management, and conducting regular formal medical science conferences.

Study summary

The purpose of this study is to evaluate the effectiveness of digital health management for intervention on Chinese population with head and neck vascular stenosis.

Eligibility

Sex
ALL
Min age
35 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: 1. Inclusion criteria of the clusters Hospitals with the qualification of "head and neck ultrasound center" in China. 2. Inclusion criteria for individuals * (1)Age ≥ 35 years old, with no restriction on gender. * (2)Patients with clinically diagnosed head and neck stenosis or occlusion, including mild, moderate or severe stenosis or occlusion of the carotid artery and mild, moderate or severe stenosis or occlusion of the intracranial artery. * (3)Ability to use a smartphone and have a mobile application installed on the handset. * (4)Subjects or their legal representatives agreed to the study and signed the project informed consent form. Exclusion Criteria: 1. Exclusion criteria for the clusters The included centers did not have the capacity to undertake the trial. 2. Exclusion criteria for individuals * (1)Combination of severe systemic diseases such as respiratory failure, renal failure, gastrointestinal bleeding, coagulation dysfunction, malignancy, etc. * (2)Patients with a life expectancy of less than 2 years or who are unable to complete the study for other reasons.

Primary outcome measure(s)

  • New-onset stroke events at 24 months — 24 months
    New-onset stroke events include ischemic stroke, transient ischemic attack, and hemorrhagic stroke.

Trial sites (1)

FacilityCityRegionStatus
First Hospital of Jilin University Changchun Jilin
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05798013 on ClinicalTrials.gov ↗ ← All trials in China